Publication:
Treatment patterns and clinical outcomes in patients with Hodgkin lymphoma from Saudi Arabia, Türkiye, and South Africa: subgroup analysis from the international multicenter retrospective B-HOLISTIC study

dc.contributor.coauthorBrittain D., Akhtar S., Rodrigues S., Patel M., Moodley D., Singh J.P., Dreosti L.M., Mohamed Z., Al-Mansour M., Alzahrani M., Shahzad Rauf M., Maghfoor I., Beşışık S.K., Boğa C., Saydam G., Huang Z., Pinchevsky Y.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorFerhanoğlu, Ahmet Burhan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-03-06T21:01:14Z
dc.date.issued2024
dc.description.abstractObjective: B-HOLISTIC was a real-world retrospective study of treatment patterns and clinical outcomes in Hodgkin lymphoma (HL) in regions outside Europe and North America. This subgroup analysis reports findings from Saudi Arabia, Türkiye, and South Africa. Materials and Methods: Patients aged ≥18 years and diagnosed with stage IIB-IV classical HL receiving frontline chemotherapy (frontline cHL) and/or with relapsed/refractory HL (RRHL) from January 2010 to December 2013 were assessed. The primary endpoint was progression-free survival (PFS) in patients with RRHL. Results: Overall, 694 patients (RRHL: n=178;frontline cHL: n=653) were enrolled. Among patients with RRHL, >80% received first salvage chemotherapy. The most common first salvage regimens were etoposide, methylprednisolone, cytarabine, and cisplatin in Saudi Arabia (78.3%) and dexamethasone, cytarabine, and cisplatin in Türkiye (36.1%) and South Africa (40%). Median PFS (95% confidence interval [CI]) in the RRHL group was 5.1 (3.0-15.9), 19.7 (7.5-not reached), and 5.2 (1.1-10.1) months in Saudi Arabia, Türkiye, and South Africa, respectively. The 5-year PFS and overall survival (95% CI) rates in patients with RRHL were 33.2% (21.6-45.2) and 78.2% (65.9-86.5) in Saudi Arabia, 42.5% (29.5-54.9) and 79.4% (67.2-87.5) in Türkiye, and 13.1% (4.2-27.0) and 53% (35.5-67.8) in South Africa, respectively. Conclusion: This study showed that the clinical outcomes in Türkiye and Saudi Arabia were generally comparable with those of Western countries during the study period, although Saudi Arabia had lower PFS rates. Conversely, the clinical outcomes in South Africa were suboptimal, emphasizing the need for novel therapies and improved progression to stem cell transplantation. These data may serve as a control group for future studies in these countries and inform clinical decision-making.
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeNational
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.4274/tjh.Galenos.2024.2024.0181
dc.identifier.issn1300-7777
dc.identifier.issue4
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85211620816
dc.identifier.urihttps://doi.org/10.4274/10.4274/tjh.Galenos.2024.2024.0181
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27970
dc.identifier.volume41
dc.keywordsDeveloping countries
dc.keywordsHematological neoplasms
dc.keywordsHematopoietic stem cell transplantation
dc.keywordsReal-world evidence
dc.keywordsResource limitations
dc.keywordsTreatment outcome
dc.language.isoeng
dc.publisherTurkish Society of Hematology
dc.relation.ispartofTurkish Journal of Hematology
dc.subjectMedicine
dc.titleTreatment patterns and clinical outcomes in patients with Hodgkin lymphoma from Saudi Arabia, Türkiye, and South Africa: subgroup analysis from the international multicenter retrospective B-HOLISTIC study
dc.title.alternativeSuudi Arabistan, Türkiye ve Güney Afrika'daki Hodgkin lenfoma hastalarında tedavi modelleri ve klinik sonuçlar: uluslararası çok merkezli retrospektif B-HOLISTIC çalışmasından alt grup analizi
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorFerhanoğlu, Ahmet Burhan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files